Preclinical News and Research

RSS

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-angiogenic drug for the treatment of "wet" age-related macular degeneration (AMD).

4 Oct 2004

Novel compound that resembles vitamin E halves the size of tumors and the ability of cancer to spread

By studying cancer in mice, researchers at The University of Texas at Austin have gained preliminary evidence that a novel compound that resembles vitamin E halves the size of tumors and the ability of cancer to spread to other body sites.

30 Sep 2004

Large-scale screening programme of tonsil tissue is the only way of identifying the true incidence of vCJD infection

A study in this week’s issue of THE LANCET describes how two different types of analysis used in conjunction on samples of tonsil tissue is the ‘gold standard’ method for confirming clinical variant CJD

30 Sep 2004

Scientists embark on a five-year study of the effects of soy isoflavones found in dietary supplements on various body tissues

A multidisciplinary team of scientists at the University of Illinois at Urbana-Champaign is embarking on a comprehensive five-year study of the effects of soy isoflavones found in dietary supplements on various body tissues.

29 Sep 2004

Cancer vaccine based on listeria bacteria shows promise

An experimental cancer vaccine using defanged listeria bacteria is showing great promise in animal studies, successfully treating new cancers that have spread into the lungs of mice.

29 Sep 2004

Phase II trials of the first second-generation antisense cancer drug to be used in patients soon to be underway

Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

28 Sep 2004

Elan and Wyeth receive patents for Alzheimer's disease treatments

Elan Corporation and Wyeth Pharmaceuticals have announced that the United States Patent and Trademark Office recently issued Neuralab Limited, a subsidiary of Elan, seven patents for the companies’ joint research on immunotherapeutic approaches to the prevention and treatment of Alzheimer’s disease.

23 Sep 2004

Scientists have corrected a flaw in cancer cells that lets them evade the normal cell-death process

Scientists at Dana-Farber Cancer Institute have corrected a flaw in cancer cells that lets them evade the normal cell-death process, and as a result they eliminated leukemia cells from mice.

21 Sep 2004

Stress response proteins offer a promising target for a novel drug guidance system

Their study, published in the September issue of the journal Cancer Cell, demonstrates how researchers can find protein tags that are unique to cancer cells and then tweak a drug delivery system to zero in on those tags and destroy the cells.

21 Sep 2004

Certain cancers might one day be cured without the use of toxic chemotherapy and radiation

The eradication of brain tumors in mice following treatment with a novel drug suggests that certain cancers might one day be cured without the use of toxic chemotherapy and radiation.

20 Sep 2004

Potential stem cells treatment for retinitis pigmentosa and other retinal degenerations

A team of researchers from The Scripps Research Institute was able to preserve visual function in mice that were genetically predisposed to developing a profound degenerative disease that destroys their retinas.

16 Sep 2004

Potential new drug for the treatment of sickle cell disease

The results were published in the June 2004 issue of The British Journal of Haematology (BJH). MX-1520 is a prodrug of vanillin, a very popular food additive generally regarded as safe (GRAS) by the FDA.

13 Sep 2004

Gene therapy holds much promise for treating aggressive human superficial bladder cancer

Gene therapy that causes the bladder to act like a “bioreactor” to produce and secrete the anti-cancer agent interferon-alpha has shown dramatic benefits in preclinical tests, say researchers at The University of Texas M. D. Anderson Cancer Center.

8 Sep 2004

Sinovac completes dosing in phase 1 human clinical testing of SARS vaccine

Sinovac Biotech Ltd. has announced that all 36 subjects of the Phase I human clinical trial for its inactivated SARS vaccine have now been vaccinated with two doses of either SARS vaccine or placebo.

7 Sep 2004

Stopping bacteria from talking to each other could help prevent serious infections

Stopping bacteria from talking to each other could help prevent serious infections say scientists from Aberdeen, in new research presented Monday at the Society for General Microbiology’s 155th Meeting at Trinity College Dublin.

7 Sep 2004

University of Nottingham research developments could mean new drugs will reach cancer patients more quickly

A £3 million grant and the establishment of a specialized business unit that will help new treatments reach cancer patients more quickly, have underlined The University of Nottingham’s place at the forefront of cancer drug development.

2 Sep 2004

New drug application for exenatide has been accepted for review

Amylin Pharmaceuticals and Eli Lilly today announced that the New Drug Application for exenatide has been accepted for review by the Food and Drug Administration.

2 Sep 2004

Interim data from human clinical trials of two AIDS vaccine candidates, named DNA.HIVA and MVA.HIVA

The interim data, from 205 volunteers in clinical trials in Kenya, Uganda and the United Kingdom, show that DNA.HIVA and MVA.HIVA are generally safe and well tolerated. However, the candidates’ ability to elicit an anti-HIV cell-mediated immune response is poor, using currently accepted measures of immune response.

30 Aug 2004

Kiwis reverse heart disease in diabetics

New Zealand biopharmaceutical company Protemix Corporation has announced the discovery of a treatment which appears to reverse heart disease in people suffering from diabetes and may lead to a more effective intervention in a major cause of death worldwide.